Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Endocannabinoid Activity Remodulation for Psychosis Liability in Youth (EARLY)

NCT06037993 is registered in ClinicalTrials.gov with University of Udine as lead sponsor.

NCT NCT06037993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06037993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Endocannabinoid Activity Remodulation for Psychosis Liability in Youth (EARLY)
Lead sponsor
University of Udine
Phase
Not applicable
Overall status
Unknown status
Start date
November 1, 2022
Completion date
November 30, 2025
Enrollment
20 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

attenuated psychotic symptoms, clinical high risk for psychosis, ultra high risk for psychosis